Lilly's Tirzepatide (Zepbound) Receives FDA Approval for Chronic Weight Management

Nov 09, 2023 09:35 CST Updated 09:35

Eli Lilly

Global Pharmaceutical R&D and Production Company

｜Edited by the Content Team of Zhong肽 Biochemical

November 8, 2023，Eli Lilly (Eli Lilly and Company) announced its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist Zepbound (tirzepatide) has been approved by the U.S. FDA for weight loss and weight maintenance in obese or overweight adult patients with weight-related comorbidities, including hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.

The FDA's approval this time is mainlyBased on the positive data from the SURMOUNT-1 and SURMOUNT-2 studies.

SURMOUNT-1 Study in Non-Type 2 Diabetic Patients with ObesityThe results showed that Tirzepatide achieved two co-primary endpoints: compared with placebo, the percentage change in body weight from baseline was greater in the Tirzepatide group, and a higher proportion of patients in the Tirzepatide group achieved at least 5% weight loss.

Compared with placebo (2.4%, 2kg), participants receiving 5mg Tirzepatide experienced an average weight loss of 16.0%, the 10mg group lost an average of 21.4%, and the 15mg group lost an average of 22.5% (equivalent to 24kg). Additionally, 89% (5mg) and 96% (10mg and 15mg) of patients in the Tirzepatide groups lost at least 5% of their body weight, compared to only 28% in the placebo group.

Results from the SURMOUNT-2 study in patients with obesity or overweight with type 2 diabetes showed that, compared to placebo, Tirzepatide (10mg and 15mg) achieved superior weight loss at 72 weeks of treatment. Compared to placebo, the study also met both co-primary endpoints and all key secondary endpoints.

AboutTirzepatide

Tirzepatide is a once-weekly GLP-1R/GIPR dual agonist that was first approved by the FDA in May 2022 for the treatment of type 2 diabetes.。GIP and GLP-1 can synergistically promote insulin secretion by pancreatic β-cells, exerting a glucose concentration-dependent hypoglycemic effect; additionally, both can improve pancreatic β-cell function and enhance insulin sensitivity; GLP-1 can delay gastric emptying, contributing to an overall hypoglycemic effect.

GIP and GLP-1 can synergistically promote insulin secretion by pancreatic β-cells, exerting a glucose concentration-dependent hypoglycemic effect; additionally, both can improve pancreatic β-cell function and enhance insulin sensitivity; GLP-1 can delay gastric emptying, playing an integrated role in lowering blood glucose.

About Eli Lilly (Eli Lilly and Company）

Eli Lilly and Company is a global leading pharmaceutical company engaged in the research, development, manufacturing, and marketing of medicines, dedicated to improving human health through innovation. Eli Lilly was founded over a century ago by Colonel Eli Lilly in Indianapolis, Indiana, in 1876. The company’s founder committed himself to producing high-quality medicines to meet genuine medical needs. Today, we remain steadfast in this mission and continue our work based on it. Globally, our employees constantly strive to develop medicines that can make a difference in people's lives and make them available to patients who truly need them. Moreover, we are also committed to enhancing public understanding of diseases and improving disease management. At the same time, we give back to society by engaging in charitable activities and volunteering.

Source:

1.Pharmcube Database

2.FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems | Eli Lilly and Company